39th SITC meeting 2024, Houston, TX, November 6-10

‍

genOway’s program at SITC 2024

‍

Our poster presentations

Below are the three posters presented by our team at the conference on Friday, 8 November, 2024 and Saturday, 9 November, 2024:

Poster #937‍

‘Tumor microenvironment composition is shaped by tumor cell line-derived xenograft subtype and tumor burden in BRGSF-HIS mice’ │ Our CD34⁺-reconstituted BRGSF-HIS mouse model, featuring functional human myeloid and lymphoid compartments, is a valuable tool to investigate immune cell infiltration in the TME, enabling the translatable assessment of the efficacy and MOA of immunotherapies targeting myeloid and lymphoid cells

Poster #877

'Assessment of γδ T-cell therapies in humanized mice' │Functional γδ T cells develop in our CD34⁺-reconstituted BRGSF-HIS mouse model, featuring functional human myeloid and lymphoid compartments, making it a useful tool to assess therapies targeting this cell population

Poster #1446‍‍

'Novel FcγR humanized mouse models enabling efficacy and PK/PD of therapeutic antibodies' │ The humanized FcγR mouse model can be used to investigate the efficacy of Fc-engineered molecules and to rank human antibodies

‍

Our clients posters

Below are posters presented by clients using our models:

Teva Pharmaceuticals

'Preclinical In Vivo Characterization of the Anti-tumor Activity of a Non-blocking PD-1 AntibodyFused to Attenuated IL-2'
Models used: BRGSF-HIS

Anaveon

'ANV700 is a novel proximity-activated IL-21 receptor agonist designed to selectively  reinvigorate tumor-reactive PD-1 expressing T cells'

'ANV600, a cis-signaling αPD-1/IL-2Rβ/γ agonist, expands both CD4 + and CD8 + tumor specific  T cells by acting in the tumor microenvironment and draining lymph nodes'
‍Model used: PD1‍‍

AstraZeneca

'AZD5863, a CLDN18.2 and CD3 binding T-cell engager, establishes a multi-faceted antitumour immune response and combines effectively with chemo-immunotherapy regimens'
‍Model used: Pan CD3